Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Warner Bros.Discovery revenue increased threefold, but it did not bring profit

2/24/23 WBD

Beyond Meat's loss doubled in 2022

2/24/23 BYND

Vladimir Putin signed the law on the refundable deduction for Gazprom Neft

2/24/23 SIBN

Block reported for 2022

2/24/23 SQ

Moderna profits in 2022 down 31%

2/23/23 MRNA

Newmont made a loss at the end of 2022

2/23/23 NEM

Alibaba reported for 9 months of fiscal year 2023

2/23/23 BABA

The NetEase announced a quarterly dividend

2/23/23 NTES

NetEase reported for 2022

2/23/23 NTES

General Director of Alrosa may become Deputy Finance Minister Alexei Moiseyev

2/23/23 ALRS